Company expects to commence Phase 3 trial of Descartes-08 in patients with myasthenia gravis in 1H2025 following recent meeting with U.S. Food ...
Cartesian Therapeutics, Inc. ( (RNAC) ) has released its Q3 earnings. Here is a breakdown of the information Cartesian Therapeutics, Inc.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback